ExomeDNAExomeDNA
Read your report

Retinal Disorder Risk and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder Reviewed by ExomeDNA Editorial Process Last reviewed: May 26, 2026

Retinal disorders encompass a broad spectrum of conditions affecting the light-sensing tissue at the back of the eye — from age-related macular degeneration and diabetic retinopathy to inherited retinal conditions and vascular disease. CFI, CFH, ARMS2, TCF7L2, and SLC16A8 are among the highest-confidence genetic signals for this broad retinal disorder phenotype in population-scale data from 635,969 diverse U.S. veterans, with the complement system, retinal metabolic transport, and diabetes-related vascular biology emerging as the major genetic risk pathways.[1] Below: how inherited variation across immune, metabolic, and vascular biology shapes susceptibility across the retinal disorder spectrum.

What are retinal disorders?

The retina is a multilayered tissue lining the back of the eye that converts light into electrical signals transmitted to the brain via the optic nerve. The retinal pigment epithelium (RPE) — a monolayer of metabolically active cells directly behind the photoreceptors — supports photoreceptor function, recycles visual pigments, phagocytoses shed outer segments, and maintains the outer blood-retinal barrier. The retinal vasculature, supplied by the central retinal artery, nourishes the inner retina while the choroidal circulation supports the RPE and outer retina.

Retinal disorders affecting this system include age-related macular degeneration (drusen accumulation, geographic atrophy, neovascular AMD); diabetic retinopathy (microvascular damage from chronic hyperglycemia — the leading cause of blindness in working-age adults); inherited retinal dystrophies (photoreceptor degeneration with genetic causes); and retinal vascular conditions including retinal vessel occlusion and abnormal vascular proliferation.

The PheCode 362 category capturing this trait encompasses this heterogeneous spectrum. The dominant genetic signal across these conditions is the complement pathway — reflecting the immune surveillance role of complement at the RPE surface that, when dysregulated, drives inflammatory retinal damage. Additional signals in metabolic and vascular biology reflect the multiple pathways through which inherited variation shapes retinal tissue health across the lifespan.

The genetics of retinal disorder risk

The genetic architecture of retinal disorders is one of the most robustly characterized in complex disease genetics — the complement pathway, retinal metabolic transport biology, and vascular growth factor signaling all contribute to the inherited susceptibility landscape. CFI, CFH, ARMS2, HTRA1, CFHR4, CFHR5, C3, SLC16A8, TCF7L2, and PDGFB are among the high-confidence genetic signals for this broad retinal disorder phenotype.[1]

635,969 diverse U.S. veterans were analyzed across 2,068 health traits in the VA Million Veteran Program (Verma et al. 2024, Science) — with complement pathway genes, retinal metabolic transport, and vascular biology loci among the 13,672 genomic risk signals identified in this ancestry-diverse genetic landscape of inherited retinal disorder susceptibility.[1]

The complement pathway is the dominant genetic risk pathway for retinal disorders, as in drusen and AMD. CFI (complement factor I) and CFH (complement factor H) are the two primary regulatory proteins that limit complement amplification at the RPE-Bruch's membrane interface; variants reducing their activity permit chronic sub-RPE inflammation that drives drusen accumulation, RPE damage, and AMD progression. ARMS2 and the adjacent HTRA1 at chromosome 10q26 are among the most replicated retinal loci in all of human genetics. C3 — the central complement activation node — and the CFHR cluster (CFHR4, CFHR5) at chromosome 1q32 complement the regulatory landscape: CFHR4 and CFHR5 are CFH-related proteins that modulate complement activity and compete with CFH for binding to C3b, with copy number variation in the CFHR cluster being a recognized AMD risk factor.

TCF7L2 — the most widely replicated type 2 diabetes genetic signal across thousands of published GWAS — appears in the genetic landscape of retinal disorders, reflecting the established metabolic-retinal connection: type 2 diabetes causes diabetic retinopathy through hyperglycemia-induced retinal vascular damage, and shared genetic pathways may connect inherited metabolic susceptibility to long-term retinal vascular health.[1]

SLC16A8 encodes MCT3 (monocarboxylate transporter 3), expressed on the basolateral membrane of RPE cells where it transports lactate from the RPE into the choroidal circulation. RPE cells receive large amounts of lactate from glycolytic photoreceptor metabolism; SLC16A8 variants impairing lactate clearance can disrupt RPE metabolic homeostasis and create conditions favoring retinal degeneration. SLC16A8 is a recognized AMD genetic signal from prior dedicated AMD GWAS, and its presence in the broad retinal disorder landscape confirms the metabolic biology of RPE maintenance as a heritable component of retinal health.

PDGFB (platelet-derived growth factor B) is a vascular growth factor critical for pericyte recruitment to capillaries throughout the body, including the retinal microvasculature. PDGF-B signaling through PDGFR-β drives pericyte attachment to retinal capillary walls; pericyte loss is a hallmark of early diabetic retinopathy, where compromised pericyte coverage leads to microaneurysms and abnormal vascular permeability. PDGFB variants affecting retinal pericyte biology contribute to the vascular dimension of retinal disorder susceptibility.

What the research says

Research base: Robust. The genetic architecture of retinal disorders is supported by the VA Million Veteran Program's genome-wide analysis of 635,969 diverse U.S. veterans across 2,068 traits (Verma et al. 2024, Science), representing one of the largest and most ancestry-diverse genetic studies available for this broad retinal phenotype.[1] The complement pathway signals (CFI, CFH, ARMS2, C3, CFHR family) have been confirmed across dozens of independent retinal GWAS, while the metabolic (TCF7L2, SLC16A8) and vascular (PDGFB) signals reflect the additional genetic architecture captured by the MVP's large, diverse, and disease-heterogeneous cohort. Robust confidence reflects both the scale and the cross-study replication of the core signals. See our methodology page for how we evaluate and apply genetic evidence in your ExomeDNA profile.

How retinal disorder genetics affects health

The retinal disorder genetic landscape captured here reflects susceptibility across multiple distinct disease pathways. For age-related macular degeneration — dominated by complement pathway genetics — the risk trajectory unfolds over decades: drusen accumulation in the fourth and fifth decades, intermediate AMD through the sixties, and potential progression to geographic atrophy or neovascular AMD threatening central vision in later life. Complement variants (CFH, CFI, C3) drive this timeline through chronic sub-RPE inflammation.

For the metabolic-retinal dimension, TCF7L2's presence reflects the genetics of type 2 diabetes susceptibility and its retinal consequences. Diabetic retinopathy affects approximately one-third of people with T2D and is the leading cause of new blindness in working-age adults. The retinal microvasculature is uniquely vulnerable to hyperglycemic damage — basement membrane thickening, pericyte loss, and eventual neovascularization follow from years of elevated blood glucose. Genetic susceptibility to T2D (captured in part by TCF7L2) represents inherited metabolic risk that eventually expresses in retinal vascular health.

A higher genetic risk score for retinal disorders reflects greater inherited susceptibility across this broad spectrum — not certainty of any specific condition developing. Multiple modifiable factors — metabolic control, UV protection, smoking avoidance — substantially influence how genetic susceptibility translates into clinical retinal outcomes over a lifetime.

Working with your retinal disorder result

What research suggests about retinal disorder risk management

  • Smoking cessation: smoking is the strongest modifiable risk factor for AMD progression — it doubles AMD risk and interacts synergistically with complement genetic variants. Smoking also accelerates diabetic retinopathy through microvascular and oxidative effects.[1]
  • Glycemic and metabolic control: given TCF7L2's presence in this genetic landscape, blood sugar management, insulin sensitivity, and metabolic health directly influence the retinal vascular component of inherited retinal disorder risk.
  • Regular retinal monitoring: dilated fundus examinations every 1–2 years allow detection of drusen, early vasculopathy, or structural changes before they threaten vision.
  • UV eye protection: quality UV-blocking sunglasses reduce photooxidative stress at the RPE, protecting against both AMD-pathway and metabolic-pathway retinal damage.
  • Blood pressure management: hypertensive retinopathy shares retinal vascular endpoints with diabetic retinopathy — blood pressure control is a shared protective factor.
  • AREDS2 supplementation: for individuals with established intermediate AMD (confirmed by eye care provider), AREDS2 supplementation has clinical evidence for slowing progression — this is a risk-stage-specific recommendation.

Retinal disorder risk connects directly to Retinal Drusen Risk, which covers the AMD/drusen-specific complement pathway in greater depth — CFI, CFH, ARMS2, and C3 are shared signals, but the Drusen page focuses specifically on sub-RPE deposits. Age-Related Macular Degeneration Risk is the downstream disease outcome for the complement-genetic component. Type 2 Diabetes Risk connects through TCF7L2 — shared inherited metabolic biology shapes both T2D onset and the retinal vascular health consequences.

For vascular adjacency, Diabetic Retinopathy Risk is the specific condition reflecting the PDGFB and TCF7L2 retinal-metabolic signals. HDL Cholesterol and CETP Genetics connects through the lipid biology underlying RPE health. Complement System Activity captures the broader immune regulatory pathway that CFI, CFH, CFHR4, and CFHR5 variants collectively shape.

Frequently asked questions

Why does TCF7L2 — a diabetes gene — appear in retinal disorder genetics?

TCF7L2 is the most replicated type 2 diabetes GWAS signal, encoding a transcription factor in the Wnt signaling pathway that regulates insulin secretion from pancreatic beta cells. Its appearance in retinal disorder genetics reflects the bidirectional biology of metabolic disease and retinal health: T2D causes diabetic retinopathy through hyperglycemic damage to the retinal microvasculature, and TCF7L2 variants that increase T2D susceptibility may share genetic pathways with retinal vascular vulnerability. This illustrates how a broadly acting metabolic transcription factor can shape retinal outcomes through downstream effects on vascular physiology.

What is SLC16A8 and why does it appear in retinal genetics?

SLC16A8 encodes MCT3 (monocarboxylate transporter 3), a lactate transporter expressed on the basolateral membrane of RPE cells. Photoreceptors are highly glycolytic and produce large amounts of lactate; RPE cells must clear this lactate via MCT3 into the choroidal circulation to maintain the metabolic homeostasis needed for photoreceptor function. Variants affecting MCT3 function impair this metabolic shuttle, accumulating lactate in the subretinal space and stressing RPE cells — contributing to retinal degeneration over time. SLC16A8 is a confirmed AMD locus from prior dedicated AMD genetics studies.

How do CFHR4 and CFHR5 relate to CFH in retinal disorder genetics?

CFH (complement factor H), CFHR4 (complement factor H-related 4), and CFHR5 (complement factor H-related 5) are all encoded in the Regulator of Complement Activation (RCA) gene cluster on chromosome 1q32. CFHR proteins share domain homology with CFH and compete for binding to C3b at complement activation surfaces. Copy number variation and sequence variants in the CFHR region can reduce CFH-mediated complement control by displacing CFH from binding sites, or conversely alter CFHR-mediated complement modulation. The extended CFHR cluster appearing in this retinal disorder GWAS reflects the composite genetic architecture of complement regulation at the RPE.

What is PDGFB and why is it relevant to retinal disorders?

PDGFB encodes platelet-derived growth factor B, which binds PDGFR-β on pericytes to drive their recruitment to and retention on capillary walls throughout the body. In the retina, pericyte coverage of capillaries is essential for vascular stability — pericyte loss is one of the earliest features of diabetic retinopathy, preceding visible vascular changes and creating conditions for microaneurysm formation and abnormal vessel permeability. PDGFB variants affecting retinal pericyte biology represent the vascular integrity dimension of inherited retinal disorder susceptibility, particularly relevant to metabolic and vascular subtypes of retinal disease.

How does this trait differ from the Retinal Drusen Risk trait?

Retinal Drusen Risk (PheCode 362.27) focuses specifically on the sub-RPE deposits that define intermediate AMD — the complement pathway is the dominant genetic architecture because drusen formation is fundamentally driven by complement dysregulation. This Retinal Disorder Risk trait (PheCode 362) is a broader category encompassing multiple retinal conditions beyond just AMD/drusen. While the complement core (CFI, CFH, ARMS2, C3) is shared, this trait also captures metabolic-vascular signals (TCF7L2, SLC16A8, PDGFB) and extended CFHR biology (CFHR4, CFHR5) that reflect retinal health across the full spectrum of inherited retinal conditions.

References

  1. Verma A, et al. (2024). Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. Science. PMID: 39024449. DOI: 10.1126/science.adj1182.

Data sources:

  • GWAS Catalog (NHGRI-EBI, accessed 2026-05-26)
  • Open Targets Platform (CC0 1.0, accessed 2026-05-26)
  • ClinVar (NCBI, accessed 2026-05-26) — entries at ≥2-star review status
  • ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-26)

This page is published by the ExomeDNA Research Team. Last reviewed: 2026-05-26.

Related traits

Browse all traits →